Trial Profile
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ProVent
- Sponsors Dendreon Corporation
- 18 Oct 2023 Planned End Date changed from 1 May 2023 to 28 Feb 2024.
- 18 Oct 2023 Planned primary completion date changed from 1 May 2023 to 31 Dec 2023.
- 15 Feb 2020 Interim results assessing comparison of sipuleucel-T (sip-T) product parameters from two phase III studies IMPACT and ProVent, presented at the 2020 Genitourinary Cancers Symposium.